The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia
Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Roy M. Pollock(C4 Therapeutics (United States)), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Raoul Tibes(BioNTech (Germany)), Jessica K. Altman(Northwestern University), Carly Campbell(Epizyme (United States)), Eric Hedrick(Florida Hospital Cancer Institute), Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), Bob Löwenberg(Unknown), Michael R. Savona(Vanderbilt University), Michelle Legler(Epizyme (United States)), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), David A. Rizzieri(Duke University), Robert A. Copeland(Unknown), Hartmut Döhner(University Hospital Ulm), Blythe Thomson(Epizyme (United States)), Scott R. Daigle(Epizyme (United States)), Alice McDonald(Millennium Engineering and Integration (United States)), Ed Olhava(Epizyme (United States)), Nigel J. Waters(Epizyme (United States))
Cited by 44
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k